查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447054

至 2030 年女性保健市場預測 - 各藥物（Actonel、Forteo、Mirena、Nuvaring、Ortho Tri-Cy Lo (28)、Premarin、Prolia、Reclast/Aclasta 和其他藥物）、配銷通路、應用和地理位置的全球分析

Women Healthcare Market Forecasts to 2030 - Global Analysis By Drug (Actonel, Forteo, Mirena, Nuvaring, Ortho Tri-Cy Lo (28), Premarin, Prolia, Reclast/Aclasta and Other Drugs), Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球女性醫療保健市場規模為 175 億美元，預計到 2030 年將達到 501 億美元，預測期內複合CAGR為 16.2%。它指的是專門針對解決各年齡層女性獨特的醫療保健需求和擔憂的醫療保健服務、產品和技術領域。這涵蓋了廣泛的醫療領域，包括生殖健康、孕產婦護理、婦科問題、乳房健康、更年期管理和各種特定性別的病症。此外，它還包括乳癌、子宮頸癌、骨質疏鬆症和其他主要影響女性的疾病等疾病的診斷工具、篩檢測試和治療。

根據美國國家骨質疏鬆基金會的數據，在全球範圍內，骨質疏鬆症影響著超過800 萬名50 歲以上的女性。根據世界衛生組織的數據，2016 年，在亞洲、非洲和南美洲等發展中國家，骨質疏鬆症患者人數約2,100 萬人。15-19 歲少女懷孕。

市場動態：

驅動因素：

女性人口增加

由於女性佔全球人口的很大一部分，她們的醫療保健需求多種多樣且複雜，跨越從青春期到更年期及以後的各個生命階段。這種人口趨勢促使人們更加關注和投資針對女性醫療保健服務和產品，以滿足其獨特的生理和醫療需求。此外，人們對預防保健的認知不斷提高、醫療技術的進步以及旨在促進婦女健康的舉措都進一步推動了市場的擴張。

阻礙因素：

財務限制

許多女性面臨經濟課題，限制了她們承擔醫療保健的能力，包括常規檢查、篩檢、藥物和專門治療。如果沒有足夠的經濟資源，女性可能會推遲尋求醫療服務或完全放棄尋求醫療服務，從而導致健康狀況惡化和醫療保健差距擴大。然而，健康保險的費用和自付費用可能令人望而卻步，特別是對於低收入個人和沒有全面保險的人來說。

機會：

婦女賦權與宣傳

隨著人們對性別平等的認知和重視不斷增強，女性開始掌控自己的健康，並要求更好地獲得針對其特定需求的醫療保健服務。這種賦權促使了針對女性健康問題的研究和開發激增，從而產生了創新的治療、診斷和預防措施。此外，宣傳工作影響了政策制定者優先考慮婦女的醫療保健，從而改善了醫療保健基礎設施和支持婦女生殖權利、孕產婦健康和避孕的政策。

威脅：

生殖權利和計劃生育的機會

法律和監管障礙以及社會恥辱可能會限制獲得全面的生殖保健服務，例如避孕、墮胎和產前護理。生殖權利的限制不僅妨礙婦女對其生殖健康做出知情選擇的能力，而且還會導致負面健康後果，包括不安全墮胎和孕產婦死亡。此外，獲得計劃生育服務的不平等對邊緣化社區產生了不成比例的影響，加劇了現有的不平等。

Covid-19 影響：

雖然世界各地的醫療保健系統專注於控制病毒，但常規的婦女健康服務卻面臨中斷，包括預防性篩檢、產前護理和避孕藥具的取得。封鎖措施和不堪重負的醫療設施導致預約延遲和服務利用率下降，加劇了現有的健康差距。然而，經濟衰退對女性的影響尤其嚴重，導致其負擔能力和獲得醫療服務的機會減少。向遠距醫療的轉變提供了一定的護理連續性，但也凸顯了數位存取和技術素養的差異，進一步影響了邊緣化人群。

Actonel 區隔市場預計將在預測期內成為最大的區隔市場

由於它用於預防和治療骨質疏鬆症（一種以骨密度降低和骨折易感性增加為特徵的疾病），Actonel 區隔市場在預計期間佔據了女性醫療保健市場的主導佔有率。透過為骨質疏鬆症管理提供有效的治療選擇，Actonel 有助於促進女性骨骼健康並降低骨折風險，從而提高她們的整體福祉和生活品質。該部門的存在不僅滿足了女性的醫療需求，還有助於提高人們對骨質疏鬆症和骨骼健康重要性的認知，從而使女性能夠為自己的健康採取積極措施。

預計子宮內膜異位症領域在預測期內複合CAGR最高

預計子宮內膜異位症領域在預測期內將出現利潤豐厚的成長。子宮內膜異位症是一種類似子宮內膜的組織在子宮外生長的疾病，影響全球數百萬名女性，導致慢性疼痛和生育問題。對子宮內膜異位症的認知和理解的提高促使了對開發先進診斷工具的投資增加，例如成像技術和生物標記測定，從而實現早期檢測和個性化治療策略。此外，製藥公司也積極開發子宮內膜異位症潛在機制的新藥，為患者提供更有效的症狀管理，並有可能改善他們的生活品質。

佔比最大的地區：

由於人們對預防保健和健康意識的增強和重視，促使對女性健康服務和產品的需求增加，北美地區在預測期內佔據了最大的市場佔有率。醫療技術的進步，特別是在婦科、產科和生殖健康等領域的進步，擴大了治療選擇並改善了結果，進一步推動了市場的區域成長。此外，政府的支持性舉措，加上強大的醫療基礎設施和保險覆蓋範圍，使該地區的女性更容易獲得醫療保健。

複合CAGR最高的地區：

由於個人化醫療利用基因檢測、生物標記分析和資料分析等先進技術，根據患者獨特的基因組成、生活方式和環境因素量身定做醫療保健策略，亞太地區預計將在預期期間大幅成長。在女性醫療保健領域，這種方法可以對乳癌、生殖健康障礙和荷爾蒙失衡等疾病進行更準確的診斷和針對性治療。此外，透過最佳化治療效果和最大限度地減少不良反應，個人化醫療不僅可以改善患者的治療效果，還可以提高整體醫療質量，使其成為推動市場成長的關鍵力量。

主要進展：

2024 年 2 月，諾華以 29 億美元收購以癌症為中心的 MorphoSys。諾華將向股東提供每股 68.00 歐元的現金，並在交易完成後將 MorphoSys 私有化，這取決於某些條件，包括 MorphoSys 股本 65% 的最低接受門檻和監管許可。

2022年9月，奧拉帕尼在中國獲得批准，成為貝伐珠單抗一線維持治療同源重組缺陷（HRD）陽性晚期卵巢癌的藥物。

2022 年 1 月，Jackson Memorial 婦女醫院、AdventHealth Celebration 和 HCA Florida Healthcare 醫療中心使用 Memic Innovative Practice 的機器人手術技術 Homins 手術系統進行婦科手術。

我們的報告提供了什麼：

  • 區域和國家層面的市場佔有率評估
  • 對新進入者的策略建議
  • 涵蓋2021年、2022年、2023年、2026年及2030年的市場資料
  • 市場趨勢（促進因素、限制因素、機會、威脅、課題、投資機會和建議）
  • 根據市場預測提出關鍵業務部門的策略建議
  • 競爭性景觀美化繪製主要共同趨勢
  • 公司概況，包括詳細的策略、財務狀況和最新發展
  • 反映最新技術進步的供應鏈趨勢

免費客製化產品：

本報告的所有客戶都將有權獲得以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 個）
    • 關鍵參與者的 SWOT 分析（最多 3 個）
  • 區域區隔
    • 根據客戶的興趣對任何主要國家的市場估計、預測和CAGR（註：取決於可行性檢查）
  • 競爭基準化分析
    • 根據產品組合、地理分佈和策略聯盟對主要參與者基準化分析

目錄

第 1 章：執行摘要

第 2 章：前言

  • 抽象的
  • 股東
  • 研究範圍
  • 研究方法論
    • 資料探勘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 研究來源
    • 主要研究來源
    • 二手研究來源
    • 假設

第 3 章：市場趨勢分析

  • 介紹
  • 促進要素
  • 限制
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • Covid-19 的影響

第 4 章：波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭競爭

第 5 章：全球女性保健市場：依藥物分類

  • 介紹
  • 阿克托內爾
  • 福爾泰奧
  • 曼月樂
  • 努瓦林
  • 鄰三環洛 (28)
  • 倍美力
  • 普羅利亞
  • 重熔/密固達
  • 其他藥物

第 6 章：全球女性保健市場：依配銷通路

  • 介紹
  • 零售藥局
  • 線上提供者
  • 醫院藥房

第 7 章：全球女性保健市場：依應用分類

  • 介紹
  • 停經
  • 荷爾蒙不孕症
  • 停經後骨質疏鬆症
  • 子宮內膜異位症
  • 避孕藥具
  • 其他應用

第 8 章：全球女性保健市場：依地理位置

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第 9 章：主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 擴充
  • 其他關鍵策略

第 10 章：公司概況

  • Agile Therapeutics Inc
  • Allergan
  • Apothecus Pharmaceutical
  • Bayer AG
  • Blairex Laboratories
  • Ferring Pharmaceuticals
  • Lupin Limited
  • Mylan NV
  • Novartis AG
  • Pfizer Inc
Product Code: SMRC25315

According to Stratistics MRC, the Global Women Healthcare Market is accounted for $17.5 billion in 2023 and is expected to reach $50.1 billion by 2030 growing at a CAGR of 16.2% during the forecast period. It refers to the sector of healthcare services, products, and technologies specifically targeted towards addressing the unique healthcare needs and concerns of women across all age groups. This encompasses a wide range of medical areas, including reproductive health, maternal care, gynecological issues, breast health, menopause management, and various gender-specific conditions. Additionally, it encompasses diagnostic tools, screening tests, and treatments for conditions such as breast cancer, cervical cancer, osteoporosis, and other diseases that predominantly affect women.

According to the National Osteoporosis Foundation, across the globe, osteoporosis affects more than 8 million women over the age of 50. According to the WHO, in 2016, in developing countries such as Asia, Africa, and South America, there were around 21 million pregnancies among adolescent girls aged 15-19 years.

Market Dynamics:

Driver:

Increasing female population

As women constitute a substantial portion of the global population, their healthcare needs are diverse and complex, spanning across various life stages from adolescence to menopause and beyond. This demographic trend is prompting greater attention and investment in women's healthcare services and products tailored to address their unique physiological and medical requirements. Moreover, rising awareness about preventive care, advancements in medical technology, and initiatives aimed at promoting women's health are further fueling market expansion.

Restraint:

Financial constraints

Many women face economic challenges that limit their ability to afford healthcare, including routine check-ups, screenings, medications, and specialized treatments. Without adequate financial resources, women may delay seeking care or forego it altogether, leading to worsened health outcomes and increased healthcare disparities. However, the cost of health insurance and out-of-pocket expenses can be prohibitive, particularly for low-income individuals and those without comprehensive coverage.

Opportunity:

Women's empowerment and advocacy

With increasing awareness and emphasis on gender equality, women are taking charge of their health and demanding better access to healthcare services tailored to their specific needs. This empowerment has led to a surge in research and development focused on women's health issues, resulting in innovative treatments, diagnostics, and preventive measures. Furthermore, advocacy efforts have influenced policymakers to prioritize women's healthcare, leading to improved healthcare infrastructure and policies supporting women's reproductive rights, maternal health, and access to contraception.

Threat:

Reproductive rights and access to family planning

Legal and regulatory barriers, along with societal stigmas, can limit access to comprehensive reproductive healthcare services such as contraception, abortion, and prenatal care. Restrictions on reproductive rights not only impede women's ability to make informed choices about their reproductive health but also contribute to negative health outcomes, including unsafe abortions and maternal mortality. Additionally, disparities in access to family planning services disproportionately affect marginalized communities, exacerbating existing inequalities.

Covid-19 Impact:

While healthcare systems worldwide focused on managing the virus, routine women's health services faced disruptions, including preventive screenings, prenatal care, and access to contraceptives. Lockdown measures and overwhelmed healthcare facilities led to postponed appointments and decreased utilization of services, exacerbating existing health disparities. However, economic downturns disproportionately affected women, leading to reduced affordability and access to healthcare services. The shift towards telemedicine offered some continuity in care but also highlighted disparities in digital access and technology literacy, further impacting marginalized populations.

The actonel segment is expected to be the largest during the forecast period

As it is utilized for the prevention and treatment of osteoporosis, a condition characterized by reduced bone density and increased susceptibility to fractures, Actonel segment commanded the dominant share in the Women Healthcare market over the projected period. By offering an effective therapeutic option for osteoporosis management, Actonel helps to promote bone health and reduce the risk of fractures in women, thereby enhancing their overall well-being and quality of life. This segment's presence not only meets the medical needs of women but also contributes to raising awareness about osteoporosis and the importance of bone health, thus empowering women to take proactive measures for their health.

The endometriosis segment is expected to have the highest CAGR during the forecast period

Endometriosis segment is estimated to witness lucrative growth during the forecast period. Endometriosis, a disorder where tissue similar to the lining of the uterus grows outside the womb, affects millions of women globally, causing chronic pain and fertility issues. The heightened awareness and understanding of endometriosis have led to increased investments in developing advanced diagnostic tools, such as imaging techniques and biomarker assays, enabling early detection and personalized treatment strategies. Additionally, pharmaceutical companies are actively engaged in the development of novel drugs targeting the underlying mechanisms of endometriosis, offering patients more effective symptom management and potentially improving their quality of life.

Region with largest share:

Owing to the increased awareness and emphasis on preventive care and wellness have led to higher demand for women's health services and products, North America region commanded the largest share of the market over the prognosis period. Advancements in medical technology, particularly in areas such as gynecology, obstetrics, and reproductive health, have expanded treatment options and improved outcomes, further driving regional growth in the market. Moreover, supportive government initiatives, coupled with robust healthcare infrastructure and insurance coverage, have made healthcare more accessible to women across the region.

Region with highest CAGR:

Asia Pacific region is estimated to witness substantial growth during the anticipated period as personalized medicine utilizes advanced technologies such as genetic testing, biomarker analysis and data analytics to customize healthcare strategies based on a patient's unique genetic makeup, lifestyle, and environmental factors. In women's healthcare, this approach enables more accurate diagnoses and targeted therapies for conditions like breast cancer, reproductive health disorders and hormonal imbalances. Furthermore, by optimizing treatment efficacy and minimizing adverse effects, personalized medicine not only improves patient outcomes but also enhances overall healthcare quality, making it a pivotal force driving growth in the market.

Key players in the market

Some of the key players in Women Healthcare market include Agile Therapeutics Inc, Allergan, Apothecus Pharmaceutical, Bayer AG, Blairex Laboratories, Ferring Pharmaceuticals, Lupin Limited, Mylan NV, Novartis AG and Pfizer Inc.

Key Developments:

In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.

In September 2022, Lynparza was given clearance in China as the first line of maintenance therapy with bevacizumab for advanced ovarian cancer with homologous recombination deficit (HRD) positivity.

In January 2022, The women's hospital at Jackson Memorial, AdventHealth Celebration, and HCA Florida Healthcare's Medical Center using the Robotic surgical technology, Homins surgical system by Memic Innovative Surgery for gynecological procedures.

Drugs Covered:

  • Actonel
  • Forteo
  • Mirena
  • Nuvaring
  • Ortho Tri-Cy Lo (28)
  • Premarin
  • Prolia
  • Reclast/Aclasta
  • Other Drugs

Distribution Channels Covered:

  • Retail Pharmacies
  • Online Providers
  • Hospital Pharmacies

Applications Covered:

  • Menopause
  • Hormonal Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraceptives
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Women Healthcare Market, By Drug

  • 5.1 Introduction
  • 5.2 Actonel
  • 5.3 Forteo
  • 5.4 Mirena
  • 5.5 Nuvaring
  • 5.6 Ortho Tri-Cy Lo (28)
  • 5.7 Premarin
  • 5.8 Prolia
  • 5.9 Reclast/Aclasta
  • 5.10 Other Drugs

6 Global Women Healthcare Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Retail Pharmacies
  • 6.3 Online Providers
  • 6.4 Hospital Pharmacies

7 Global Women Healthcare Market, By Application

  • 7.1 Introduction
  • 7.2 Menopause
  • 7.3 Hormonal Infertility
  • 7.4 Postmenopausal Osteoporosis
  • 7.5 Endometriosis
  • 7.6 Contraceptives
  • 7.7 Other Applications

8 Global Women Healthcare Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Agile Therapeutics Inc
  • 10.2 Allergan
  • 10.3 Apothecus Pharmaceutical
  • 10.4 Bayer AG
  • 10.5 Blairex Laboratories
  • 10.6 Ferring Pharmaceuticals
  • 10.7 Lupin Limited
  • 10.8 Mylan NV
  • 10.9 Novartis AG
  • 10.10 Pfizer Inc

List of Tables

  • Table 1 Global Women Healthcare Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 3 Global Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 4 Global Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 5 Global Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 6 Global Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 7 Global Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 8 Global Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 9 Global Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 10 Global Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 11 Global Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 12 Global Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 15 Global Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 16 Global Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 18 Global Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 19 Global Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 20 Global Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 21 Global Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 22 Global Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 23 North America Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 24 North America Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 25 North America Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 26 North America Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 27 North America Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 28 North America Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 29 North America Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 30 North America Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 31 North America Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 32 North America Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 33 North America Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 34 North America Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 35 North America Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 36 North America Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 37 North America Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 38 North America Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 39 North America Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 40 North America Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 41 North America Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 42 North America Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 43 North America Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 44 North America Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 45 Europe Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 46 Europe Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 47 Europe Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 48 Europe Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 49 Europe Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 50 Europe Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 51 Europe Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 52 Europe Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 53 Europe Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 54 Europe Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 55 Europe Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 56 Europe Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 57 Europe Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 58 Europe Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 59 Europe Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 60 Europe Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 62 Europe Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 63 Europe Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 64 Europe Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 65 Europe Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 66 Europe Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 67 Asia Pacific Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 68 Asia Pacific Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 69 Asia Pacific Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 70 Asia Pacific Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 71 Asia Pacific Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 72 Asia Pacific Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 73 Asia Pacific Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 74 Asia Pacific Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 75 Asia Pacific Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 76 Asia Pacific Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 77 Asia Pacific Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 78 Asia Pacific Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 79 Asia Pacific Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 80 Asia Pacific Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 81 Asia Pacific Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 82 Asia Pacific Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 83 Asia Pacific Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 84 Asia Pacific Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 85 Asia Pacific Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 86 Asia Pacific Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 87 Asia Pacific Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 88 Asia Pacific Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 89 South America Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 90 South America Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 91 South America Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 92 South America Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 93 South America Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 94 South America Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 95 South America Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 96 South America Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 97 South America Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 98 South America Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 99 South America Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 100 South America Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 101 South America Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 102 South America Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 103 South America Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 104 South America Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 105 South America Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 106 South America Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 107 South America Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 108 South America Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 109 South America Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 110 South America Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 111 Middle East & Africa Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 112 Middle East & Africa Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 113 Middle East & Africa Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 114 Middle East & Africa Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 115 Middle East & Africa Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 116 Middle East & Africa Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 117 Middle East & Africa Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 118 Middle East & Africa Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 119 Middle East & Africa Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 120 Middle East & Africa Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 121 Middle East & Africa Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 122 Middle East & Africa Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 123 Middle East & Africa Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 124 Middle East & Africa Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 125 Middle East & Africa Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 126 Middle East & Africa Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 127 Middle East & Africa Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 128 Middle East & Africa Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 129 Middle East & Africa Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 130 Middle East & Africa Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 131 Middle East & Africa Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 132 Middle East & Africa Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)